Halozyme Therapeutics Company Profile (NASDAQ:HALO)

About Halozyme Therapeutics

Halozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of enzymes segment. This segment also includes research and development, and bulk rHuPH20 manufacturing activities conducted under its collaborative agreements with third parties, and product sales of Hylenex recombinant. Its development pipeline consists of clinical-stage product candidates in oncology. Its lead oncology program is PEGPH20 (polyethylene glycol (PEG)ylated recombinant human hyaluronidase), a molecular entity being developed for the systemic treatment of tumors, which accumulate HA. It is in Phase II and Phase III clinical testing for PEGPH20 in stage IV pancreatic ductal adenocarcinoma (Studies 109-202 and 109-301); Phase Ib clinical testing in non-small cell lung cancer (Study 107-201), and in Phase Ib clinical testing in non-small cell lung cancer and gastric cancer (Study 107-101).

Industry, Sector and Symbol:

Sector: Medical
Industry: Biotechnology
Sub-Industry: Biotechnology
Exchange: NASDAQ
Symbol: HALO
CUSIP: 40637H10

Key Metrics:

Previous Close: $12.41
50 Day Moving Average: $10.72
200 Day Moving Average: $9.90
52-Week Range: $6.96 - $18.65
Trailing P/E Ratio: N/A
Foreward P/E Ratio: -21.03
P/E Growth: 0.00
Market Cap: $1.56B
Outstanding Shares: 127,958,000
Beta: 2.19

Profitability:

Net Margins: -44.90%
Return on Equity: -234.15%
Return on Assets: -28.27%

Debt:

Debt-to-Equity Ratio: 20.65%
Current Ratio: 7.31%
Quick Ratio: 7.04%

Additional Links:

Companies Related to Halozyme Therapeutics:

Consensus Ratings for Halozyme Therapeutics (NASDAQ:HALO) (?)

Ratings Breakdown:	1 Sell Rating, 6 Buy Ratings
Consensus Rating:	Buy (Score: 2.71)
Consensus Price Target:	$16.13 (29.94% upside)

Analysts' Ratings History for Halozyme Therapeutics (NASDAQ:HALO)

Show:

Date	Firm	Action	Rating	Price Target
9/16/2016	Piper Jaffray Cos.	Boost Price Target	Overweight	$15.00 -> $18.00
9/8/2016	Wells Fargo & Co.	Reiterated Rating	Buy
6/6/2016	Canaccord Genuity	Reiterated Rating	Buy	$11.00
5/10/2016	Jefferies Group	Reiterated Rating	Sell	$6.75
3/9/2016	JMP Securities	Lower Price Target	Market Outperform	$22.00 -> $20.00
2/24/2016	Barclays PLC	Lower Price Target	Overweight	$27.00 -> $16.00
11/18/2015	Citigroup Inc.	Initiated Coverage	Buy	$25.00
6/22/2015	JPMorgan Chase & Co.	Boost Price Target	Overweight	$20.00 -> $25.00
6/1/2015	MLV & Co.	Reiterated Rating	Buy	$20.00
4/20/2015	BMO Capital Markets	Set Price Target	Buy	$26.00

(Data available from 9/29/2014 forward)

Earnings History for Halozyme Therapeutics (NASDAQ:HALO)

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
11/7/2016
8/9/2016	Q216	($0.27)	($0.21)	$29.94 million	$33.30 million	View	N/A
5/9/2016	Q116	($0.20)	($0.16)	$29.65 million	$42.50 million	View	N/A
2/29/2016	Q415	($0.08)	$0.03	$37.06 million	$52.20 million	View	Listen
11/9/2015	Q315	($0.16)	($0.19)	$24.01 million	$20.80 million	View	N/A
8/10/2015	Q215	($0.09)	$0.02	$24.84 million	$43.40 million	View	Listen
5/11/2015	Q115	($0.13)	($0.12)	$19.40 million	$18.70 million	View	Listen
3/2/2015	Q414	($0.07)	($0.04)	$25.60 million	$30.38 million	View	N/A
11/10/2014	Q314	($0.14)	($0.16)	$16.50 million	$14.60 million	View	N/A
8/11/2014	Q214	($0.14)	($0.13)	$13.71 million	$18.40 million	View	N/A
5/12/2014	Q114	($0.14)	($0.22)	$13.37 million	$12.00 million	View	N/A
2/27/2014	Q413	($0.17)	($0.19)	$21.80 million	$12.50 million	View	N/A
11/8/2013	Q313	($0.15)	($0.17)	$14.62 million	$16.00 million	View	N/A
8/7/2013	Q2 2013	($0.13)	($0.13)	$11.29 million	$14.50 million	View	N/A
5/8/2013	Q1 2013	($0.15)	($0.17)	$7.05 million	$11.83 million	View	N/A
2/25/2013	Q4 2012	($0.16)	($0.04)	$7.32 million	$21.80 million	View	N/A
11/8/2012	Q312	($0.13)	($0.18)	$6.09 million	$5.33 million	View	N/A
8/6/2012		($0.15)	($0.13)			View	N/A
5/7/2012		($0.11)	$0.14			View	N/A
3/9/2012		($0.16)	($0.18)			View	N/A
11/7/2011		($0.03)	$0.05			View	N/A

(Data available from 1/1/2011 forward)

Earnings Estimates for Halozyme Therapeutics (NASDAQ:HALO)

Current Year EPS Consensus Estimate: $-0.89 EPS
Next Year EPS Consensus Estimate: $-0.59 EPS

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2016	2	($0.20)	($0.17)	($0.19)
Q2 2016	1	($0.28)	($0.28)	($0.28)
Q3 2016	1	($0.24)	($0.24)	($0.24)
Q4 2016	1	($0.30)	($0.30)	($0.30)

(Data provided by Zacks Investment Research)

Dividend History for Halozyme Therapeutics (NASDAQ:HALO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Halozyme Therapeutics (NASDAQ:HALO)

Insider Ownership Percentage: 16.60%
Institutional Ownership Percentage: 80.41%

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
8/20/2015	Laurie Stelzer	CFO	Buy	10,000	$17.24	$172,400.00
6/18/2015	Kenneth J Kelley	Director	Sell	20,000	$21.00	$420,000.00
9/16/2014	David A Ramsay	CFO	Buy	25,000	$8.90	$222,500.00
9/16/2014	Helen Torley	CEO	Buy	50,000	$8.92	$446,000.00
8/19/2014	John Stuart Patton	Director	Sell	75,000	$9.96	$747,000.00
5/15/2014	Robert Engler	Director	Sell	126,700	$7.56	$957,852.00
9/16/2013	John Stuart Patton	Director	Sell	75,000	$9.13	$684,750.00
8/19/2013	H. Michael Shepard	VP	Sell	10,000	$7.11	$71,100.00
8/14/2013	Kathryn Falberg	Director	Buy	100,000	$6.82	$682,000.00
11/29/2012	Robert Engler	Director	Buy	15,000	$5.57	$83,550.00
11/14/2012	James P Shaffer	VP	Buy	20,000	$5.22	$104,400.00
11/13/2012	Kathryn E Falberg	Director	Buy	50,000	$5.21	$260,500.00
8/27/2012	Kenneth J Kelley	Director	Buy	20,000	$5.70	$114,000.00
8/13/2012	Gregory Ian Frost	CEO	Buy	2,000	$5.50	$11,000.00

(Data available from 1/1/2013 forward)

Latest Headlines for Halozyme Therapeutics (NASDAQ:HALO)

Date	Headline
	Halozyme Therapeutics Up 19.6% Since SmarTrend Uptrend Call (HALO) (NASDAQ:HALO) www.mysmartrend.com - September 29 at 10:26 AM
	Active biotech company shares in the news: Halozyme Therapeutics, Inc. (NASDAQ:HALO), Incyte Corporation ... - The Voice Registrar (NASDAQ:HALO) voiceregistrar.com - September 28 at 5:12 PM
	Biotech Stocks Worth a Closer Look: Halozyme Therapeutics, Inc. (NASDAQ:HALO), BioMarin Pharmaceutical Inc ... - The Voice Registrar (NASDAQ:HALO) voiceregistrar.com - September 28 at 10:14 AM
	HC Stocks Updates! Concordia International Corp (CXRX), Halozyme Therapeutics, Inc. (NASDAQ:HALO) - share market updates (press release) (NASDAQ:HALO) sharemarketupdates.com - September 26 at 5:28 PM
	Active biotech company shares in the news: Halozyme Therapeutics, Inc. (NASDAQ:HALO), PTC Therapeutics, Inc ... - The Voice Registrar (NASDAQ:HALO) voiceregistrar.com - September 26 at 5:28 PM
	Biotech Stocks To Put On Your Watch List: Halozyme Therapeutics, Inc. (NASDAQ:HALO), Spectrum Pharmaceuticals ... - The Voice Registrar (NASDAQ:HALO) voiceregistrar.com - September 23 at 10:20 AM
	Biotech stocks for your portfolio: Halozyme Therapeutics, Inc. (HALO ... - The Independent Republic (NASDAQ:HALO) theindependentrepublic.com - September 22 at 8:27 AM
	Trading the Biotech News: Threshold Pharmaceuticals Inc. (NASDAQ:THLD), Halozyme Therapeutics, Inc. (NASDAQ ... - The Voice Registrar (NASDAQ:HALO) voiceregistrar.com - September 22 at 8:27 AM
	Uptrend Call Working As Halozyme Therapeutics Stock Rises 15.8% (HALO) (NASDAQ:HALO) www.mysmartrend.com - September 21 at 3:35 PM
	How Halozyme Uses Enzymes to Deliver Drugs (HALO) (NASDAQ:HALO) www.investopedia.com - September 19 at 5:27 PM
	HC Stocks Watchful! Galena Biopharma Inc (GALE), Halozyme ... - share market updates (press release) (NASDAQ:HALO) sharemarketupdates.com - September 19 at 9:56 AM
	Time To Put On The Watch List? - Halozyme Therapeutics, Inc. (NASDAQ:HALO), Spectrum Pharmaceuticals, Inc ... - The Voice Registrar (NASDAQ:HALO) voiceregistrar.com - September 16 at 5:13 PM
	One Reason Why Halozyme Therapeutics (HALO) Stock Is Climbing Today (NASDAQ:HALO) www.thestreet.com - September 16 at 5:13 PM
	Active Biotech Stock News: Spectrum Pharmaceuticals, Inc. (SPPI), Halozyme Therapeutics, Inc. (HALO) - The Independent Republic (NASDAQ:HALO) theindependentrepublic.com - September 16 at 9:15 AM
	New Market Research Report: Halozyme Therapeutics, Inc. (NASDAQ:HALO) reports.pr-inside.com - September 14 at 5:28 PM
	News review of 2 biotech stocks: Achillion Pharmaceuticals, Inc ... - The Voice Registrar (NASDAQ:HALO) voiceregistrar.com - September 13 at 10:09 AM
	HC Stocks in Top Row= Halozyme Therapeutics, Inc. (HALO), Edwards Lifesciences Corp (NYSE:EW) - share market updates (press release) (NASDAQ:HALO) sharemarketupdates.com - September 12 at 10:08 AM
	Will Halozyme Therapeutics, Inc. (NASDAQ:HALO) Surprise Analysts? - Investor Newswire (NASDAQ:HALO) www.investornewswire.com - September 11 at 4:58 PM
	Halozyme Therapeutics To Present At The Bank Of America Merrill Lynch 2016 Global Health Care Conference - PR Newswire (press release) (NASDAQ:HALO) www.prnewswire.com - September 10 at 9:51 AM
	Biotech Stocks Worth a Closer Look: Halozyme Therapeutics, Inc. (NASDAQ:HALO), Clovis Oncology, Inc. (NASDAQ ... - The Voice Registrar (NASDAQ:HALO) voiceregistrar.com - September 10 at 9:51 AM
	Halozyme Therapeutics : To Present At Upcoming Healthcare Conferences (NASDAQ:HALO) www.4-traders.com - September 9 at 5:10 PM
	ETF’s with exposure to Halozyme Therapeutics, Inc. : September 9, 2016 (NASDAQ:HALO) www.capitalcube.com - September 9 at 5:10 PM
	Halozyme Therapeutics To Present At The Bank Of America Merrill Lynch 2016 ... (NASDAQ:HALO) www.prnewswire.com - September 8 at 5:16 PM
	Halozyme Therapeutics To Present At The Bank Of America Merrill Lynch 2016 ... (NASDAQ:HALO) www.prnewswire.com - September 8 at 5:16 PM
	Halozyme Therapeutics To Present At The Bank Of America Merrill Lynch 2016 Global Health Care Conference (NASDAQ:HALO) finance.yahoo.com - September 8 at 5:16 PM
	Halozyme Therapeutics To Present At The Bank Of America Merrill Lynch 2016 Global Health Care Conference (NASDAQ:HALO) finance.yahoo.com - September 8 at 5:16 PM
	News review of 2 biotech stocks: ZIOPHARM Oncology, Inc ... - The Voice Registrar (NASDAQ:HALO) voiceregistrar.com - September 6 at 5:24 PM
	Halozyme Therapeutics Names Gergen COO (NASDAQ:HALO) sdbj.com - September 3 at 9:57 AM
	Upcoming Earnings Report: Halozyme Therapeutics, Inc. (NASDAQ:HALO) - The Voice Registrar (NASDAQ:HALO) voiceregistrar.com - September 2 at 5:17 PM
	Stock Update (NASDAQ:HALO): Halozyme Therapeutics, Inc. Appoints Mark J. Gergen As Chief Operating Officer - Smarter Analyst (NASDAQ:HALO) www.smarteranalyst.com - September 2 at 10:14 AM
	Halozyme Therapeutics (HALO) Appoints New COO (NASDAQ:HALO) www.streetinsider.com - September 1 at 5:17 PM
	Stock Update (NASDAQ:HALO): Halozyme Therapeutics, Inc. Appoints Mark J. Gergen As Chief Operating Officer (NASDAQ:HALO) www.smarteranalyst.com - September 1 at 5:17 PM
	9:01 am Halozyme Therapeutics names Mark Gergen as COO (NASDAQ:HALO) finance.yahoo.com - September 1 at 5:17 PM
	Halozyme Names Mark J. Gergen As Chief Operating Officer (NASDAQ:HALO) www.publicnow.com - September 1 at 5:17 PM
	HALOZYME THERAPEUTICS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exh (NASDAQ:HALO) biz.yahoo.com - September 1 at 5:17 PM
	Shares Slipping Lower Over the Past Month: Halozyme Therapeutics, Inc. (NASDAQ:HALO) - Post News (NASDAQ:HALO) www.kentuckypostnews.com - September 1 at 8:18 AM
	Halozyme Therapeutics To Present At Upcoming Healthcare Conferences (NASDAQ:HALO) finance.yahoo.com - September 1 at 8:18 AM
	Active biotech company shares in the news: Halozyme Therapeutics, Inc. (NASDAQ:HALO), BioMarin Pharmaceutical ... - The Voice Registrar (NASDAQ:HALO) voiceregistrar.com - August 29 at 5:15 PM
	ETF’s with exposure to Halozyme Therapeutics, Inc. : August 29, 2016 (NASDAQ:HALO) www.capitalcube.com - August 29 at 5:15 PM
	Ratings & Crowd Appeal on Halozyme Therapeutics, Inc. (NASDAQ:HALO) - Post News (NASDAQ:HALO) www.kentuckypostnews.com - August 23 at 5:31 PM
	Research Report Coverage on Biotech Stocks -- Halozyme Therapeutics, Achillion Pharma, Aegerion Pharma and ... - PR Newswire (press release) (NASDAQ:HALO) www.prnewswire.com - August 23 at 5:31 PM
	Research Report Coverage on Biotech Stocks -- Halozyme Therapeutics, Achillion Pharma, Aegerion Pharma and Chimerix (NASDAQ:HALO) www.kswo.com - August 23 at 9:45 AM
	The Key Numbers To Watch From Halozyme Therapeutics, Inc. (NASDAQ:HALO)'s Earnings - The Voice Registrar (NASDAQ:HALO) voiceregistrar.com - August 19 at 8:18 AM
	HALOZYME THERAPEUTICS INC Financials (NASDAQ:HALO) finance.yahoo.com - August 18 at 5:23 PM
	Trading the Biotech News: Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN), Halozyme Therapeutics, Inc. (NASDAQ ... - The Voice Registrar (NASDAQ:HALO) voiceregistrar.com - August 18 at 8:22 AM
	ETF’s with exposure to Halozyme Therapeutics, Inc. : August 15, 2016 (NASDAQ:HALO) www.capitalcube.com - August 15 at 5:34 PM
	Halozyme Therapeutics Increases Estimate for Yearly Net Revenue (NASDAQ:HALO) sdbj.com - August 14 at 5:14 PM
	Halozyme Increases Estimate for Yearly Net Revenue (NASDAQ:HALO) sdbj.com - August 12 at 5:26 PM
	Halozyme Therapeutics, Inc. :HALO-US: Earnings Analysis: Q2, 2016 By the Numbers : August 12, 2016 (NASDAQ:HALO) www.capitalcube.com - August 12 at 5:26 PM
	8-K: HALOZYME THERAPEUTICS INC (NASDAQ:HALO) www.traderplanet.com - August 10 at 5:40 PM